Nouscom
Clinical-stage biotech developing neoantigen-based cancer immunotherapies.
€120MSeries D
ParticipantActivity from announced rounds
Clinical-stage biotech developing neoantigen-based cancer immunotherapies.
RNA therapeutics designed to restore expression of silenced genes